Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin89.4%+1.0pp89.6%+1.4pp88.6%-0.4pp88.5%+0.2pp88.4%+1.2pp
Operating margin-7.8%-18.9pp-8.7%-21.0pp-5.4%-14.5pp9.6%+5.4pp11.2%+13.4pp
Net margin-3.7%-13.0pp-5.4%-16.5pp-2.8%-12.0pp9.7%+8.9pp9.3%+11.9pp
Returns
Return on equity-2.8%-9.1pp-3.7%-11.2pp-1.9%-8.1pp6.4%+5.8pp6.3%+8.0pp
Return on invested capital-6.4%-11.8pp-6.3%-12.8pp-3.8%-10.1pp5.3%+2.5pp5.4%+7.4pp
Efficiency
Asset turnover0.5×0.0×0.5×0.0×0.5×0.0×0.5×0.0×0.5×+0.1×
Liquidity
Current ratio-0.5×1.9×-0.4×1.8×-0.4×2.6×+0.7×2.4×+0.7×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA-3.9×-3.4×-3×-2.8×-2.3×-2.3×-0.8×-0.7×-0.5×-0.2×
Per Share
Book value per share$18.68+1.2%$18.81+1.6%$18.56+3.2%$18.78+9.3%$18.45+10.5%
Valuation
Market capitalization$2.98B+62.8%$2.85B+42.7%$2.68B+56.3%$1.77B+21.0%$1.83B-1.9%
Price / sales3.8×+1.1×+0.9×3.9×+1.3×2.7×+0.3×2.7×-0.4×
Price / book2.8×+1.0×2.7×+0.8×2.6×+0.9×1.7×+0.1×1.8×-0.2×
EV / EBITDA76.6×+65.3×94.3×+82.2×53×+41.0×11.5×-1.6×11.3×-14.5×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Supernus Pharmaceuticals's profit margins?
Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
Where do Supernus Pharmaceuticals's ratios come from?
Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.